Global Sustained-release Medicine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sustained-release Medicine Market Research Report 2024
Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
According to Mr Accuracy reports’s new survey, global Sustained-release Medicine market is projected to reach US$ 55040 million in 2034, increasing from US$ 34850 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sustained-release Medicine market research.
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sustained-release Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Sustained-release Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Distribution Channel)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Distribution Channel Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
According to Mr Accuracy reports’s new survey, global Sustained-release Medicine market is projected to reach US$ 55040 million in 2034, increasing from US$ 34850 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sustained-release Medicine market research.
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sustained-release Medicine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Sustained-release Medicine report covers below items
Chapter 1Product Basic Information (Definition, Type and Distribution Channel)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Distribution Channel Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices